Keyphrases
Interleukin-2
100%
Metastatic Renal Cell Carcinoma (mRCC)
100%
Low-dose interleukin-2
100%
High Dose
37%
Response Rate
25%
Clinical Response
25%
Medical Center
25%
Israel
12%
Lymphocytes
12%
Dose Effect
12%
Lymphocyte Activation
12%
Metastasis
12%
Mitogen
12%
Tumor Cells
12%
Lung Metastasis
12%
Rapid Progression
12%
Adverse Reactions
12%
Phase II Clinical Study
12%
Activated Cells
12%
Liver Metastasis
12%
LAK Cells
12%
Adoptive Immunotherapy
12%
Lumbar Vertebrae
12%
Pelvis
12%
Discharge from Hospital
12%
Medicine and Dentistry
Low Drug Dose
100%
Kidney Metastasis
100%
Immunotherapy
100%
Interleukin 2
100%
Drug Megadose
33%
Clinical Study
11%
Mitogenic Agent
11%
Tumor Cell
11%
Adverse Event
11%
Liver Metastasis
11%
Metastatic Carcinoma
11%
Lung Metastasis
11%
Pelvis
11%
Lymphocyte Activation
11%
Adoptive Immunotherapy
11%
Lumbar Vertebra
11%
Lymphocyte
11%
Diseases
11%
Immunology and Microbiology
Low Drug Dose
100%
Interleukin 2
100%
Carcinoma Cell
100%
Immunotherapy
100%
Drug Megadose
33%
Mitogen
11%
Adoptive Immunotherapy
11%
Tumor Cell
11%
Lumbar Vertebra
11%
Lymphocyte Activation
11%
Pelvis
11%
Lymphocyte
11%
Pharmacology, Toxicology and Pharmaceutical Science
Kidney Metastasis
100%
Immunotherapy
100%
Interleukin 2
100%
Clinical Study
11%
Adverse Event
11%
Mitogenic Agent
11%
Liver Metastasis
11%
Lung Metastasis
11%
Neoplasm
11%
Diseases
11%